PHARMACOKINETIC AND PHARMACODYNAMIC ASPECTS OF POLYPEPTIDE DELIVERY

被引:31
作者
MAZER, NA
机构
[1] TheraTech, Inc. and Department of Pharmaceutics, University of Utah, Salt Lake City
关键词
input function; modelling; pharmacodynamics; pharmacokinetics; polypeptides;
D O I
10.1016/0168-3659(90)90146-K
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The rational design and development of drug delivery systems for polypeptide compounds requires a quantitative understanding of the pharmacokinetics (PK) and pharmacodynamics (PD) of the compound in the intended therapeutic indication. In particular it is necessary to define the characteristics of the input function, i.e. the rate and time course of systemic drug input, that will maximize the therapeutic effect, minimize unwanted side effects and prevent tachyphylaxis from occurring. This paper reviews the general concepts of input function, PK and PD, and illustrates these concepts using two examples from the literature: (1) Sandoz compound SMS 201-995 and (2) gonadotropin-releasing hormone (GnRH). For SMS 201-995, a continuous (zero-order) input function is shown to be optimal for suppressing growth hormone secretion in the treatment of acromegaly. For GnRH, a pulsatile input function is optimal for stimulating pituitary gonadotropin secretion, whereas continuous input leads to a paradoxical suppression of gonadotropin secretion. These examples further illustrate the types of novel experimental approaches, using programmable infusion pumps, that are needed for investigating the relationship between PK and PD, and for defining the optimal input function experimentally. In addition, we show how mathematical models may be used to describe the interrelationships between input function, PK and PD. For SMS 201-995, a model based on the "effect compartment" concept offers a self-consistent description of the linkage between PK and PD and provides insight into the superiority of continuous input in the treatment of acromegaly. For GnRH, the complex relationship between input function and gonadotropin secretion is modelled on the basis of heuristic concepts that relate the time-averaged occupancy of the GnRH-receptors (by GnRH) to the expression of GnRH-receptors by the pituitary (i.e. down and up regulation). Together these examples illustrate the diversity of input functions that will be needed in polypeptide delivery and the novel experimental and theoretical approaches required for defining them. © 1990.
引用
收藏
页码:343 / 356
页数:14
相关论文
共 50 条
  • [21] Pharmacodynamic and pharmacokinetic drug interactions
    Pleuvry, Barbara J.
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2005, 6 (04) : 129 - +
  • [22] Pharmacokinetic and pharmacodynamic characteristics of aripiprazole
    Soygur, Haldun
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 18 : S1 - S6
  • [23] A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis
    Cattrall, J. W. S.
    Asin-Prieto, E.
    Freeman, J.
    Troconiz, I. F.
    Kirby, A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2019, 38 (12) : 2311 - 2321
  • [24] A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis
    J. W. S. Cattrall
    E. Asín-Prieto
    J. Freeman
    I. F. Trocóniz
    A. Kirby
    European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 : 2311 - 2321
  • [25] Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling
    Meibohm, B
    Derendorf, H
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (10) : 401 - 413
  • [26] Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation
    Dudhipala, Narendar
    Veerabrahma, Kishan
    DRUG DELIVERY, 2016, 23 (02) : 395 - 404
  • [27] Theoretical pharmacokinetic and pharmacodynamic simulations of drug delivery mediated by blood-brain barrier transporters
    Doan, KMM
    Boje, KMK
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2000, 21 (07) : 261 - 278
  • [28] THE PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS OF RAMIPRIL WITH PROPRANOLOL
    VANGRIENSVEN, JMT
    SEIBERTGRAFE, M
    SCHOEMAKER, HC
    FROLICH, M
    COHEN, AF
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 45 (03) : 255 - 260
  • [29] Physiological, pharmacokinetic, and pharmacodynamic changes in space
    Graebe, A
    Schuck, EL
    Lensing, P
    Putcha, L
    Derendorf, H
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (08) : 837 - 853
  • [30] Pharmacokinetic-pharmacodynamic relationships for analgesics
    Suri, A
    Estes, KS
    Geisslinger, G
    Derendorf, H
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (08) : 307 - 323